查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1421001

心血管藥物市場 - 2023-2031 年全球產業分析、規模、佔有率、成長、趨勢與預測

Cardiovascular Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031
出版日期: | 出版商: Transparency Market Research | 英文 241 Pages | 商品交期: 2-10個工作天內

價格

心血管藥物市場 - 報告範圍

TMR 關於全球帕金森氏症治療市場的報告研究了過去以及當前的成長趨勢和機會，以獲得 2023 年至 2031 年預測期內市場指標的寶貴見解。該報告提供了全球帕金森氏症治療的收入2017- 2031年期間的市場，考慮2023年為基準年，2031年為預測年。該報告也提供了2023年至2031年全球帕金森氏症治療市場的年複合成長率（CAGR %）。

該報告是經過廣泛研究後編寫的。初級研究涉及大部分研究工作，其中分析師對關鍵意見領袖、行業領導者和輿論製造者進行了採訪。二次研究涉及參考主要參與者的產品文獻、年度報告、新聞稿和相關文件，以了解帕金森氏症治療市場。

市場概況
2023年市場價值 1,428 億美元
2031 年市場價值 1956 億美元
CAGR 3.8%

該報告深入研究了全球帕金森氏症治療市場的競爭格局。全球帕金森氏症治療市場的主要參與者已經確定，並對每位參與者的不同屬性進行了分析。公司概況、財務狀況、最新發展和 SWOT 是本報告中介紹的全球帕金森氏症治療市場參與者的屬性。

目錄

第1章：前言

第 2 章：假設與研究方法

第 3 章：執行摘要：全球市場

第 4 章：市場概覽

  • 介紹
  • 概述
  • 市場動態
  • 2017-2031年全球市場分析與預測

第 5 章：關鍵見解

  • 管道分析
  • 主要產品/品牌分析
  • 主要併購
  • COVID-19 大流行對該行業的影響

第 6 章：全球市場分析與預測：依藥物類別

  • 簡介與定義
  • 主要發現/進展
  • 市場價值預測：依藥品類別，2017-2031
    • 腎素-血管張力素系統阻斷劑
      • ACE抑制劑
      • 血管張力素受體阻斷劑
    • BETA受體阻斷劑
    • 利尿劑
    • 抗凝血劑
      • 抗凝血劑
      • 血小板聚集抑制劑
    • 降血脂藥
    • 其他降血壓藥
    • 鈣通道阻斷劑
    • 其他
  • 市場吸引力分析：依藥品類別

第 7 章：全球市場分析與預測：依指標分類

  • 簡介與定義
  • 主要發現/進展
  • 市場價值預測：依指標分類，2017-2031
    • 高血壓
    • 高血脂症
    • 冠狀動脈疾病
    • 週邊動脈疾病
    • 心律不整
    • 其他
  • 市場吸引力分析：依指標分類

第 8 章：全球市場分析與預測：按配銷通路

  • 簡介與定義
  • 主要發現/進展
  • 市場價值預測：按配銷通路，2017-2031
    • 醫院藥房
    • 零售藥房
    • 網路藥房
  • 市場吸引力分析：按配銷通路

第 9 章：全球市場分析與預測：按地區

  • 主要發現
  • 市場價值預測：按地區，2017-2031
    • 北美洲
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲
  • 市場吸引力分析：按地區

第 10 章：北美市場分析與預測

第 11 章：歐洲市場分析與預測

第 12 章：亞太市場分析與預測

第 13 章：拉丁美洲市場分析與預測

  • 市場價值預測：按配銷通路，2017-2031
    • 醫院藥房
    • 零售藥房
    • 網路藥房
  • 市場價值預測：依國家/次區域分類，2017-2031
    • 巴西
    • 墨西哥
    • 拉丁美洲其他地區
  • 市場吸引力分析
    • 按藥物類別
    • 按指示
    • 按配銷通路
    • 按國家/次區域

    第 14 章：中東和非洲市場分析與預測

    第 15 章：競爭格局

    • 市場參與者 - 競爭矩陣（依公司層級和規模）
    • 市佔率分析：依公司分類（2022 年）
    • 公司簡介
      • AstraZeneca
      • Pfizer Inc.
      • Novartis AG
      • Merck & Co. Inc.
      • Bristol-Myers Squibb Company
      • Bayer AG
      • Sanofi
      • Boehringer Ingelheim GmbH
      • F. Hoffmann-La Roche Ltd.
      • Abbott Laboratories
      • Gilead Sciences, Inc.
      • Johnson & Johnson
      • Astellas Pharma, Inc.
      • Eli Lilly and Company
      • Otsuka Holdings Co., Ltd.
      • Takeda Pharmaceuticals Company Ltd.
    • Product Code: TMRGL33281

    Cardiovascular Drugs Market - Scope of Report

    TMR's report on the global Parkinson's disease therapeutics market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global Parkinson's disease therapeutics market for the period 2017-2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global Parkinson's disease therapeutics market from 2023 to 2031.

    The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the Parkinson's disease therapeutics market.

    Market Snapshot
    Market Value in 2023US$ 142.8 Bn
    Market Value in 2031US$ 195.6 Bn
    CAGR3.8%

    Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global Parkinson's disease therapeutics market.

    The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global Parkinson's disease therapeutics market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global Parkinson's disease therapeutics market.

    The report delves into the competitive landscape of the global Parkinson's disease therapeutics market. Key players operating in the global Parkinson's disease therapeutics market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global Parkinson's disease therapeutics market profiled in this report.

    Key Questions Answered in Global Parkinson's disease therapeutics Market Report:

    • What is the sales/revenue generated by Parkinson's disease therapeutics across all regions during the forecast period?
    • What are the opportunities in the global Parkinson's disease therapeutics market?
    • What are the major drivers, restraints, opportunities, and threats in the market?
    • Which regional market is set to expand at the fastest CAGR during the forecast period?
    • Which segment is expected to generate the highest revenue globally in 2031?
    • Which segment is projected to expand at the highest CAGR during the forecast period?
    • What are the market positions of different companies operating in the global market?

    Cardiovascular Drugs Market - Research Objectives and Research Approach

    The comprehensive report on the global Parkinson's disease therapeutics market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

    For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

    The report analyzes the global Parkinson's disease therapeutics market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global Parkinson's disease therapeutics market.

    Table of Contents

    1. Preface

    • 1.1. Market Definition and Scope
    • 1.2. Market Segmentation
    • 1.3. Key Research Objectives
    • 1.4. Research Highlights

    2. Assumptions and Research Methodology

    3. Executive Summary: Global Cardiovascular Drugs Market

    4. Market Overview

    • 4.1. Introduction
      • 4.1.1. Product Definition
      • 4.1.2. Industry Evolution/Developments
    • 4.2. Overview
    • 4.3. Market Dynamics
      • 4.3.1. Drivers
      • 4.3.2. Restraints
      • 4.3.3. Opportunities
    • 4.4. Global Cardiovascular Drugs Market Analysis and Forecast, 2017-2031

    5. Key Insights

    • 5.1. Pipeline Analysis
    • 5.2. Key Product/Brand Analysis
    • 5.3. Key Mergers & Acquisitions
    • 5.4. COVID-19 Pandemic Impact on Industry

    6. Global Cardiovascular Drugs Market Analysis and Forecast, by Drug Class

    • 6.1. Introduction & Definition
    • 6.2. Key Findings/Developments
    • 6.3. Market Value Forecast, by Drug Class, 2017-2031
      • 6.3.1. Renin-Angiotensin System Blockers
        • 6.3.1.1. ACE Inhibitors
        • 6.3.1.2. Angiotensin Receptor Blockers
      • 6.3.2. Beta Blockers
      • 6.3.3. Diuretics
      • 6.3.4. Anti-Clotting Agents
        • 6.3.4.1. Anti-Coagulants
        • 6.3.4.2. Platelet Aggregation Inhibitors
      • 6.3.5. Antihyperlipidemics
      • 6.3.6. Other Antihypertensive
      • 6.3.7. Calcium Channel Blockers
      • 6.3.8. Others
    • 6.4. Market Attractiveness Analysis, by Drug Class

    7. Global Cardiovascular Drugs Market Analysis and Forecast, by Indication

    • 7.1. Introduction & Definition
    • 7.2. Key Findings/Developments
    • 7.3. Market Value Forecast, by Indication, 2017-2031
      • 7.3.1. Hypertension
      • 7.3.2. Hyperlipidemia
      • 7.3.3. Coronary Artery Disease
      • 7.3.4. Peripheral Artery Disease
      • 7.3.5. Arrhythmia
      • 7.3.6. Others
    • 7.4. Market Attractiveness Analysis, by Indication

    8. Global Cardiovascular Drugs Market Analysis and Forecast, by Distribution Channel

    • 8.1. Introduction & Definition
    • 8.2. Key Findings/Developments
    • 8.3. Market Value Forecast, by Distribution Channel, 2017-2031
      • 8.3.1. Hospital Pharmacy
      • 8.3.2. Retail Pharmacy
      • 8.3.3. Online Pharmacy
    • 8.4. Market Attractiveness Analysis, by Distribution Channel

    9. Global Cardiovascular Drugs Market Analysis and Forecast, by Region

    • 9.1. Key Findings
    • 9.2. Market Value Forecast, by Region, 2017-2031
      • 9.2.1. North America
      • 9.2.2. Europe
      • 9.2.3. Asia Pacific
      • 9.2.4. Latin America
      • 9.2.5. Middle East & Africa
    • 9.3. Market Attractiveness Analysis, by Region

    10. North America Cardiovascular Drugs Market Analysis and Forecast

    • 10.1. Introduction
    • 10.2. Key Findings
    • 10.3. Market Value Forecast, by Drug Class, 2017-2031
      • 10.3.1. Renin-Angiotensin System Blockers
        • 10.3.1.1. ACE Inhibitors
        • 10.3.1.2. Angiotensin Receptor Blockers
      • 10.3.2. Beta Blockers
      • 10.3.3. Diuretics
      • 10.3.4. Anti-Clotting Agents
        • 10.3.4.1. Anti-Coagulants
        • 10.3.4.2. Platelet Aggregation Inhibitors
      • 10.3.5. Antihyperlipidemics
      • 10.3.6. Other Antihypertensive
      • 10.3.7. Calcium Channel Blockers
      • 10.3.8. Others
    • 10.4. Market Value Forecast, by Indication, 2017-2031
      • 10.4.1. Hypertension
      • 10.4.2. Hyperlipidemia
      • 10.4.3. Coronary Artery Disease
      • 10.4.4. Peripheral Artery Disease
      • 10.4.5. Arrhythmia
      • 10.4.6. Others
    • 10.5. Market Value Forecast, by Distribution Channel, 2017-2031
      • 10.5.1. Hospital Pharmacy
      • 10.5.2. Retail Pharmacy
      • 10.5.3. Online Pharmacy
    • 10.6. Market Value Forecast, by Country, 2017-2031
      • 10.6.1. U.S.
      • 10.6.2. Canada
    • 10.7. Market Attractiveness Analysis
      • 10.7.1. By Drug Class
      • 10.7.2. By Indication
      • 10.7.3. By Distribution Channel
      • 10.7.4. By Country

    11. Europe Cardiovascular Drugs Market Analysis and Forecast

    • 11.1. Introduction
    • 11.2. Key Findings
    • 11.3. Market Value Forecast, by Drug Class, 2017-2031
      • 11.3.1. Renin-Angiotensin System Blockers
        • 11.3.1.1. ACE Inhibitors
        • 11.3.1.2. Angiotensin Receptor Blockers
      • 11.3.2. Beta Blockers
      • 11.3.3. Diuretics
      • 11.3.4. Anti-Clotting Agents
        • 11.3.4.1. Anti-Coagulants
        • 11.3.4.2. Platelet Aggregation Inhibitors
      • 11.3.5. Antihyperlipidemics
      • 11.3.6. Other Antihypertensive
      • 11.3.7. Calcium Channel Blockers
      • 11.3.8. Others
    • 11.4. Market Value Forecast, by Indication, 2017-2031
      • 11.4.1. Hypertension
      • 11.4.2. Hyperlipidemia
      • 11.4.3. Coronary Artery Disease
      • 11.4.4. Peripheral Artery Disease
      • 11.4.5. Arrhythmia
      • 11.4.6. Others
    • 11.5. Market Value Forecast, by Distribution Channel, 2017-2031
      • 11.5.1. Hospital Pharmacy
      • 11.5.2. Retail Pharmacy
      • 11.5.3. Online Pharmacy
    • 11.6. Market Value Forecast, by Country/Sub-region, 2017-2031
      • 11.6.1. Germany
      • 11.6.2. U.K.
      • 11.6.3. France
      • 11.6.4. Italy
      • 11.6.5. Spain
      • 11.6.6. Rest of Europe
    • 11.7. Market Attractiveness Analysis
      • 11.7.1. By Drug Class
      • 11.7.2. By Indication
      • 11.7.3. By Distribution Channel
      • 11.7.4. By Country/Sub-region

    12. Asia Pacific Cardiovascular Drugs Market Analysis and Forecast

    • 12.1. Introduction
    • 12.2. Key Findings
    • 12.3. Market Value Forecast, by Drug Class, 2017-2031
      • 12.3.1. Renin-Angiotensin System Blockers
        • 12.3.1.1. ACE Inhibitors
        • 12.3.1.2. Angiotensin Receptor Blockers
      • 12.3.2. Beta Blockers
      • 12.3.3. Diuretics
      • 12.3.4. Anti-Clotting Agents
        • 12.3.4.1. Anti-Coagulants
        • 12.3.4.2. Platelet Aggregation Inhibitors
      • 12.3.5. Antihyperlipidemics
      • 12.3.6. Other Antihypertensive
      • 12.3.7. Calcium Channel Blockers
      • 12.3.8. Others
    • 12.4. Market Value Forecast, by Indication, 2017-2031
      • 12.4.1. Hypertension
      • 12.4.2. Hyperlipidemia
      • 12.4.3. Coronary Artery Disease
      • 12.4.4. Peripheral Artery Disease
      • 12.4.5. Arrhythmia
      • 12.4.6. Others
    • 12.5. Market Value Forecast, by Distribution Channel, 2017-2031
      • 12.5.1. Hospital Pharmacy
      • 12.5.2. Retail Pharmacy
      • 12.5.3. Online Pharmacy
    • 12.6. Market Value Forecast, by Country/Sub-region, 2017-2031
      • 12.6.1. China
      • 12.6.2. Japan
      • 12.6.3. India
      • 12.6.4. Australia & New Zealand
      • 12.6.5. Rest of Asia Pacific
    • 12.7. Market Attractiveness Analysis
      • 12.7.1. By Drug Class
      • 12.7.2. By Indication
      • 12.7.3. By Distribution Channel
      • 12.7.4. By Country/Sub-region

    13. Latin America Cardiovascular Drugs Market Analysis and Forecast

    • 13.1. Introduction
    • 13.2. Key Findings
    • 13.3. Market Value Forecast, by Drug Class, 2017-2031
      • 13.3.1. Renin-Angiotensin System Blockers
        • 13.3.1.1. ACE Inhibitors
        • 13.3.1.2. Angiotensin Receptor Blockers
      • 13.3.2. Beta Blockers
      • 13.3.3. Diuretics
      • 13.3.4. Anti-Clotting Agents
        • 13.3.4.1. Anti-Coagulants
        • 13.3.4.2. Platelet Aggregation Inhibitors
      • 13.3.5. Antihyperlipidemics
      • 13.3.6. Other Antihypertensive
      • 13.3.7. Calcium Channel Blockers
      • 13.3.8. Others
    • 13.4. Market Value Forecast, by Indication, 2017-2031
        • 13.4.1.1. Hypertension
        • 13.4.1.2. Hyperlipidemia
        • 13.4.1.3. Coronary Artery Disease
        • 13.4.1.4. Peripheral Artery Disease
        • 13.4.1.5. Arrhythmia
        • 13.4.1.6. Others
    • 13.5. Market Value Forecast, by Distribution Channel, 2017-2031
      • 13.5.1. Hospital Pharmacy
      • 13.5.2. Retail Pharmacy
      • 13.5.3. Online Pharmacy
    • 13.6. Market Value Forecast, by Country/Sub-region, 2017-2031
      • 13.6.1. Brazil
      • 13.6.2. Mexico
      • 13.6.3. Rest of Latin America
    • 13.7. Market Attractiveness Analysis
      • 13.7.1. By Drug Class
      • 13.7.2. By Indication
      • 13.7.3. By Distribution Channel
      • 13.7.4. By Country/Sub-region

    14. Middle East & Africa Cardiovascular Drugs Market Analysis and Forecast

    • 14.1. Introduction
    • 14.2. Key Findings
    • 14.3. Market Value Forecast, by Drug Class, 2017-2031
      • 14.3.1. Renin-Angiotensin System Blockers
        • 14.3.1.1. ACE Inhibitors
        • 14.3.1.2. Angiotensin Receptor Blockers
      • 14.3.2. Beta Blockers
      • 14.3.3. Diuretics
      • 14.3.4. Anti-Clotting Agents
        • 14.3.4.1. Anti-Coagulants
        • 14.3.4.2. Platelet Aggregation Inhibitors
      • 14.3.5. Antihyperlipidemics
      • 14.3.6. Other Antihypertensive
      • 14.3.7. Calcium Channel Blockers
      • 14.3.8. Others
    • 14.4. Market Value Forecast, by Indication, 2017-2031
      • 14.4.1. Hypertension
      • 14.4.2. Hyperlipidemia
      • 14.4.3. Coronary Artery Disease
      • 14.4.4. Peripheral Artery Disease
      • 14.4.5. Arrhythmia
      • 14.4.6. Others
    • 14.5. Market Value Forecast, by Distribution Channel, 2017-2031
      • 14.5.1. Hospital Pharmacy
      • 14.5.2. Retail Pharmacy
      • 14.5.3. Online Pharmacy
    • 14.6. Market Value Forecast, by Country/Sub-region, 2017-2031
      • 14.6.1. GCC Countries
      • 14.6.2. South Africa
      • 14.6.3. Rest of Middle East & Africa
    • 14.7. Market Attractiveness Analysis
      • 14.7.1. By Drug Class
      • 14.7.2. By Indication
      • 14.7.3. By Distribution Channel
      • 14.7.4. By Country/Sub-region

    15. Competition Landscape

    • 15.1. Market Player - Competitive Matrix (by Tier and Size of Companies)
    • 15.2. Market Share Analysis, by Company (2022)
    • 15.3. Company Profiles
      • 15.3.1. AstraZeneca
        • 15.3.1.1. Company Overview
        • 15.3.1.2. Product Portfolio
        • 15.3.1.3. SWOT Analysis
        • 15.3.1.4. Financial Overview
        • 15.3.1.5. Strategic Overview
      • 15.3.2. Pfizer Inc.
        • 15.3.2.1. Company Overview
        • 15.3.2.2. Product Portfolio
        • 15.3.2.3. SWOT Analysis
        • 15.3.2.4. Financial Overview
        • 15.3.2.5. Strategic Overview
      • 15.3.3. Novartis AG
        • 15.3.3.1. Company Overview
        • 15.3.3.2. Product Portfolio
        • 15.3.3.3. SWOT Analysis
        • 15.3.3.4. Financial Overview
        • 15.3.3.5. Strategic Overview
      • 15.3.4. Merck & Co. Inc.
        • 15.3.4.1. Company Overview
        • 15.3.4.2. Product Portfolio
        • 15.3.4.3. SWOT Analysis
        • 15.3.4.4. Financial Overview
        • 15.3.4.5. Strategic Overview
      • 15.3.5. Bristol-Myers Squibb Company
        • 15.3.5.1. Company Overview
        • 15.3.5.2. Product Portfolio
        • 15.3.5.3. SWOT Analysis
        • 15.3.5.4. Financial Overview
        • 15.3.5.5. Strategic Overview
      • 15.3.6. Bayer AG
        • 15.3.6.1. Company Overview
        • 15.3.6.2. Product Portfolio
        • 15.3.6.3. SWOT Analysis
        • 15.3.6.4. Financial Overview
        • 15.3.6.5. Strategic Overview
      • 15.3.7. Sanofi
        • 15.3.7.1. Company Overview
        • 15.3.7.2. Product Portfolio
        • 15.3.7.3. SWOT Analysis
        • 15.3.7.4. Financial Overview
        • 15.3.7.5. Strategic Overview
      • 15.3.8. Boehringer Ingelheim GmbH
        • 15.3.8.1. Company Overview
        • 15.3.8.2. Product Portfolio
        • 15.3.8.3. SWOT Analysis
        • 15.3.8.4. Financial Overview
        • 15.3.8.5. Strategic Overview
      • 15.3.9. F. Hoffmann-La Roche Ltd.
        • 15.3.9.1. Company Overview
        • 15.3.9.2. Product Portfolio
        • 15.3.9.3. SWOT Analysis
        • 15.3.9.4. Financial Overview
        • 15.3.9.5. Strategic Overview
      • 15.3.10. Abbott Laboratories
        • 15.3.10.1. Company Overview
        • 15.3.10.2. Product Portfolio
        • 15.3.10.3. SWOT Analysis
        • 15.3.10.4. Financial Overview
        • 15.3.10.5. Strategic Overview
      • 15.3.11. Gilead Sciences, Inc.
        • 15.3.11.1. Company Overview
        • 15.3.11.2. Product Portfolio
        • 15.3.11.3. SWOT Analysis
        • 15.3.11.4. Financial Overview
        • 15.3.11.5. Strategic Overview
      • 15.3.12. Johnson & Johnson
        • 15.3.12.1. Company Overview
        • 15.3.12.2. Product Portfolio
        • 15.3.12.3. SWOT Analysis
        • 15.3.12.4. Financial Overview
        • 15.3.12.5. Strategic Overview
      • 15.3.13. Astellas Pharma, Inc.
        • 15.3.13.1. Company Overview
        • 15.3.13.2. Product Portfolio
        • 15.3.13.3. SWOT Analysis
        • 15.3.13.4. Financial Overview
        • 15.3.13.5. Strategic Overview
      • 15.3.14. Eli Lilly and Company
        • 15.3.14.1. Company Overview
        • 15.3.14.2. Product Portfolio
        • 15.3.14.3. SWOT Analysis
        • 15.3.14.4. Financial Overview
        • 15.3.14.5. Strategic Overview
      • 15.3.15. Otsuka Holdings Co., Ltd.
        • 15.3.15.1. Company Overview
        • 15.3.15.2. Product Portfolio
        • 15.3.15.3. SWOT Analysis
        • 15.3.15.4. Financial Overview
        • 15.3.15.5. Strategic Overview
      • 15.3.16. Takeda Pharmaceuticals Company Ltd.
        • 15.3.16.1. Company Overview
        • 15.3.16.2. Product Portfolio
        • 15.3.16.3. SWOT Analysis
        • 15.3.16.4. Financial Overview
        • 15.3.16.5. Strategic Overview

    List of Tables

    • Table 01: Global Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2017-2031
    • Table 02: Global Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Indication, 2017-2031
    • Table 03: Global Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2017-2031
    • Table 04: Global Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Region, 2017-2031
    • Table 05: North America Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Country, 2017-2031
    • Table 06: North America Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2017-2031
    • Table 07: North America Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Indication, 2017-2031
    • Table 08: North America Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2017-2031
    • Table 09: Europe Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
    • Table 10: Europe Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2017-2031
    • Table 11: Europe Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Indication, 2017-2031
    • Table 12: Europe Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2017-2031
    • Table 13: Asia Pacific Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
    • Table 14: Asia Pacific Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2017-2031
    • Table 15: Asia Pacific Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Indication, 2017-2031
    • Table 16: Asia Pacific Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2017-2031
    • Table 17: Latin America Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
    • Table 18: Latin America Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2017-2031
    • Table 19: Latin America Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Indication, 2017-2031
    • Table 20: Latin America Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2017-2031
    • Table 21: Middle East & Africa Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
    • Table 22: Middle East & Africa Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2017-2031
    • Table 23: Middle East & Africa Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Indication, 2017-2031
    • Table 24: Middle East & Africa Cardiovascular Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2017-2031

    List of Figures

    • Figure 01: Global Cardiovascular Drugs Market Size (US$ Mn) and Distribution (%), by Region, 2022 and 2031
    • Figure 02: Global Cardiovascular Drugs Market Revenue (US$ Mn), by Drug Class, 2022
    • Figure 03: Global Cardiovascular Drugs Market Value Share, by Drug Class, 2022
    • Figure 04: Global Cardiovascular Drugs Market Revenue (US$ Mn), by Indication, 2022
    • Figure 05: Global Cardiovascular Drugs Market Value Share, by Indication, 2022
    • Figure 06: Global Cardiovascular Drugs Market Revenue (US$ Mn), by Distribution Channel, 2022
    • Figure 07: Global Cardiovascular Drugs Market Value Share, by Distribution Channel, 2022
    • Figure 08: Global Cardiovascular Drugs Market Value Share, by Region, 2022
    • Figure 09: Global Cardiovascular Drugs Market Value (US$ Mn) Forecast, 2023-2031
    • Figure 10: Global Cardiovascular Drugs Market Value Share Analysis, by Drug Class, 2022 and 2031
    • Figure 11: Global Cardiovascular Drugs Market Attractiveness Analysis, by Drug Class, 2023-2031
    • Figure 12: Global Cardiovascular Drugs Market Value Share Analysis, by Indication, 2022 and 2031
    • Figure 13: Global Cardiovascular Drugs Market Attractiveness Analysis, by Indication, 2023-2031
    • Figure 14: Global Cardiovascular Drugs Market Value Share Analysis, by Distribution Channel, 2022 and 2031
    • Figure 15: Global Cardiovascular Drugs Market Attractiveness Analysis, by Distribution Channel, 2022-2031
    • Figure 16: Global Cardiovascular Drugs Market Value Share Analysis, by Region, 2022 and 2031
    • Figure 17: Global Cardiovascular Drugs Market Attractiveness Analysis, by Region, 2022-2031
    • Figure 18: North America Cardiovascular Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017-2031
    • Figure 19: North America Cardiovascular Drugs Market Attractiveness Analysis, by Country, 2023-2031
    • Figure 20: North America Cardiovascular Drugs Market Value Share Analysis, by Country, 2022 and 2031
    • Figure 21: North America Cardiovascular Drugs Market Value Share Analysis, by Drug Class, 2022 and 2031
    • Figure 22: North America Cardiovascular Drugs Market Value Share Analysis, by Indication, 2022 and 2031
    • Figure 23: North America Cardiovascular Drugs Market Value Share Analysis, by Distribution Channel, 2022 and 2031
    • Figure 24: North America Cardiovascular Drugs Market Attractiveness Analysis, by Drug Class, 2023-2031
    • Figure 25: North America Cardiovascular Drugs Market Attractiveness Analysis, by Indication, 2023-2031
    • Figure 26: North America Cardiovascular Drugs Market Attractiveness Analysis, by Distribution Channel, 2023-2031
    • Figure 27: Europe Cardiovascular Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017-2031
    • Figure 28: Europe Cardiovascular Drugs Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
    • Figure 29: Europe Cardiovascular Drugs Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
    • Figure 30: Europe Cardiovascular Drugs Market Value Share Analysis, by Drug Class, 2022 and 2031
    • Figure 31: Europe Cardiovascular Drugs Market Value Share Analysis, by Indication, 2022 and 2031
    • Figure 32: Europe Cardiovascular Drugs Market Value Share Analysis, by Distribution Channel, 2022 and 2031
    • Figure 33: Europe Cardiovascular Drugs Market Attractiveness Analysis, by Drug Class, 2023-2031
    • Figure 34: Europe Cardiovascular Drugs Market Attractiveness Analysis, by Indication, 2023-2031
    • Figure 35: Europe Cardiovascular Drugs Market Attractiveness Analysis, by Distribution Channel, 2023-2031
    • Figure 36: Asia Pacific Cardiovascular Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017-2031
    • Figure 37: Asia Pacific Cardiovascular Drugs Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
    • Figure 38: Asia Pacific Cardiovascular Drugs Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
    • Figure 39: Asia Pacific Cardiovascular Drugs Market Value Share Analysis, by Drug Class, 2022 and 2031
    • Figure 40: Asia Pacific Cardiovascular Drugs Market Value Share Analysis, by Indication, 2022 and 2031
    • Figure 41: Asia Pacific Cardiovascular Drugs Market Value Share Analysis, by Distribution Channel, 2022 and 2031
    • Figure 42: Asia Pacific Cardiovascular Drugs Market Attractiveness Analysis, by Drug Class, 2023-2031
    • Figure 43: Asia Pacific Cardiovascular Drugs Market Attractiveness Analysis, by Indication, 2023-2031
    • Figure 44: Asia Pacific Cardiovascular Drugs Market Attractiveness Analysis, by Distribution Channel, 2023-2031
    • Figure 45: Latin America Cardiovascular Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017-2031
    • Figure 46: Latin America Cardiovascular Drugs Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
    • Figure 47: Latin America Cardiovascular Drugs Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
    • Figure 48: Latin America Cardiovascular Drugs Market Value Share Analysis, by Drug Class, 2022 and 2031
    • Figure 49: Latin America Cardiovascular Drugs Market Value Share Analysis, by Indication, 2022 and 2031
    • Figure 50: Latin America Cardiovascular Drugs Market Value Share Analysis, by Distribution Channel, 2022 and 2031
    • Figure 51: Latin America Cardiovascular Drugs Market Attractiveness Analysis, by Drug Class, 2023-2031
    • Figure 52: Latin America Cardiovascular Drugs Market Attractiveness Analysis, by Indication, 2023-2031
    • Figure 53: Latin America Cardiovascular Drugs Market Attractiveness Analysis, by Distribution Channel, 2023-2031
    • Figure 54: Middle East & Africa Cardiovascular Drugs Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2017-2031
    • Figure 55: Middle East & Africa Cardiovascular Drugs Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
    • Figure 56: Middle East & Africa Cardiovascular Drugs Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
    • Figure 57: Middle East & Africa Cardiovascular Drugs Market Value Share Analysis, by Drug Class, 2022 and 2031
    • Figure 58: Middle East & Africa Cardiovascular Drugs Market Value Share Analysis, by Indication, 2022 and 2031
    • Figure 59: Middle East & Africa Cardiovascular Drugs Market Value Share Analysis, by Distribution Channel, 2022 and 2031
    • Figure 60: Middle East & Africa Cardiovascular Drugs Market Attractiveness Analysis, by Drug Class, 2023-2031
    • Figure 61: Middle East & Africa Cardiovascular Drugs Market Attractiveness Analysis, by Indication, 2023-2031
    • Figure 62: Middle East & Africa Cardiovascular Drugs Market Attractiveness Analysis, by Distribution Channel, 2023-2031